Endocrinologic and Metabolic Drugs Advisory Committee Meeting: FDA briefing document, NDA206321, Liraglutide injection 3 mg, Sponsor Novo Nordisk
doi: 10.1016/j.fertnstert.2015.01.019
Em pesquisa, utilizado para investigar mecanismos moleculares de sinalizao celular e regulao fisiolgica experimental , sempre em ambientes laboratoriais controlados
For weight management, it is approved for adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity
The effects of smoking and zinc on the oxidative reactions of human neutrophils
Singh S, Mishra A, Srivastava N, Shukla R, Shukla S